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Abstract 
This review considers the role of melatonin as an oncostatic agent and particularly as to how it relates to the 
mechanisms by which melatonin regulates glucose metabolism in cancer cells.  Many tumor cells adopt a means of 
glucose utilization that is different from that of healthy cells.  Thus, these cancer cells rapidly take up and metabolize 
glucose and after it is converted to pyruvate, they accelerate the production of lactate which is abundantly released into 
the circulation.  The change in metabolism that cancer cells makes is referred to as aerobic glycolysis.  The switch to 
aerobic glycolysis affords cancer cells major advantages in terms of an accelerated rate of ATP production and the 
synthesis of abundant molecular building blocks required for rapid proliferation, invasion, and metastasis.  In normal 
cells, the bulk of the pyruvate formed is shunted into the mitochondria for conversion to acetyl-CoA.  Melatonin is both 
produced and released in a circadian manner from the pineal gland and likely by the mitochondria of all normal cells in 
a non-circadian manner.  In cancer cells, melatonin forces them to abandon aerobic glycolysis and function 
phenotypically as a normal cell by upregulating the enzyme, pyruvate dehydrogenase complex, that catalyzes pyruvate 
to acetyl-CoA; this is presumably achieved by the direct or indirect inhibition of pyruvate dehydrogenase kinase, which 
normally downregulates pyruvate dehydrogenase complex.  By depriving cancer cells of aerobic glycolysis, melatonin 
reverts them to a normal cell phenotype thereby reducing the rapid cell proliferation and aggressive nature of cancer 
cells. 
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The unusually wide distribution and vast 
functional diversity of melatonin likely greatly 
exceeds what was envisaged by those working in 
the field just two decades ago.  Melatonin is a 
highly conserved molecule that is present in 
ancient prokaryotes and possibly in all eukaryotic 
plant and animal cells.  While its initial function is 
presumed to have been that as an antioxidant (Tan 
et al., 2013; Zhao et al., 2019) it broadened its 
physiological repertoire during evolution to the 
point where it is difficult to identify cellular 
functions in which it is not somehow involved 
(Reiter et al., 2010, 2020a; Tordjman et al., 2017; 
Majidinia et al., 2018; Prado et al., 2018; Cardinali 
2019; Mortezaee et al., 2019).  In the current 
review, we only address the role of melatonin in 
solid tumors that manifest the Warburg effect in 
which the cancer cells favor cytosolic glycolysis 
instead of mitochondrial oxidative phosphorylation 
(Schwartz et al., 2017).  Glucose, the major 
macronutrient of all cells, is utilized for energy 
production in the form of ATP when it is oxidized.  
One common cytosolic end product of glucose 
oxidation is pyruvate, which in normal cells, enters 
the mitochondria where during respiration it is 
converted to CO2.  Rapidly growing and 
proliferating tumor cells hijack those processes by 
preventing pyruvate metabolism in mitochondria; 
rather they convert pyruvate to lactate in the 
cytosol (Liberti & Locasale 2016; Xu et al., 2015).  
The rate of glucose uptake and the production of 
lactate are strikingly elevated in cancer cells.  
Reducing the impact of mitochondrial glucose 
oxidation affords cancer cells advantages which 
they use to enhance their ability to overgrow or 
proliferate and to become invasive and metastatic. 
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Two pools of melatonin: releasable (circadian) and non-releasable (non-circadian) 
For decades it was assumed that melatonin was exclusively a biosynthetic product of the vertebrate 
pineal gland.  However, after its discovery in unicells (Poeggeler & Hardeland 1994) and in plants (Dubbels 
et al., 1995; Hattori et al., 1995), organisms that do not have a pineal, it was apparent that relegating 
melatonin synthesis only to this gland was clearly an error.  Even in vertebrates, melatonin was eventually 
identified in organs other than the pineal, and the blood levels were not diminished when the pineal gland 
was removed (Bubenik 1980; Acuna-Castroviejo et al., 2014).  Subsequently, melatonin was identified in 
the mitochondria of rodent brain and liver cells where, as in the gut, its levels are not depressed by surgical 
removal of the pineal (Venegas et al., 2012). 
Because of these findings, in 2013 we proposed that mitochondria and chloroplasts are subcellular 
sites of melatonin production and, therefore, it occurs in every animal and plant cell (Tan et al., 2013).  That 
mitochondria and chloroplasts are the factories for melatonin synthesis was also based on the observation 
that a primitive prokaryote, i.e., a bacterium, was identified as containing immunoreactive melatonin 
(Manchester et al., 1995). 
The endosymbiotic theory surmises that mitochondria and chloroplasts originated bacteria that 
already produced melatonin that were phagocytized by early eukaryotes (Gabaldon, 2018).  During the 
subsequent evolution of more complex eukaryotes, the synthetic melatonin activity of these organelles was 
retained such that animals and plants that currently exist as well as those that have become extinct all 
do/had synthesized melatonin (Figure 1).  In this scheme, alphaproteobacteria would have been the 
precursors of mitochondria while photosynthetic cyanobacteria developed into chloroplasts.  Verification of 
melatonin synthesis in both mitochondria (He et al., 2016; Suofu et al., 2017); and chloroplasts (Back et al., 




























Figure 1 This figure illustrates the presumed universal presence of melatonin in the animal and plant kingdoms.  Given 
that melatonin is believed to have evolved in prokaryotic bacteria which, after their engulfment by early eukaryotes, 
eventually became mitochondria and chloroplasts, all extinct and currently-surviving organisms had/do generate 
melatonin in every mitochondria/chloroplast-containing cell. 
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Even though melatonin is manufactured 
in every cell, only the pineal gland is capable of 
discharging this product into the cerebrospinal 
fluid (CSF) and blood with the primary route of 
secretion probably being into the third ventricular 
CSF at least for its regulation of the biological 
clock (Tricoire et al., 2002; Reiter et al., 2014).  In 
every species tested, pinealectomy lowers blood 
melatonin levels to near zero.  Why only 
pinealocytes are capable of releasing melatonin 
into body fluids while other cells are not has yet to 
be determined. 
These differences allow for the 
classification of two pools of melatonin, i.e., a 
releasable (circadian) pool and a non-releasable 
(non-circadian) pool (Figure 2).  The light:dark 
dependent circadian variations in CSF/blood 
melatonin levels are derived from the pineal gland 
and impact all circadian genes in every cell in 
vertebrates.  Conversely, the non-releasable pool is 
concerned with the metabolism of the cell in which 
it is produced and, possibly via a paracrine means, 
of adjacent cells.  For example, melatonin released 
from the mucosal cells of the duodenum induces 
the liberation of bicarbonate ions from adjacent 
mucosal cells (Sjoblom & Flemstrom, 2001).  
Likewise, in the retina, locally-generated 
melatonin influences dopamine metabolism and, 
even though retinal melatonin exhibits a rhythm 
similar to that in the pineal, it never escapes into 
the systemic circulation (Dubocovich 1984; 
Zawilska 1994).  The non-releasable melatonin 
pool does not enter the CSF or blood and is not 
























Figure 2 Examples of the releasable and non-releasable pools of melatonin are represented in this figure.  The pineal 
gland (A) of mammals is the only tissue that liberates melatonin into the cerebrospinal fluid (CSF) and blood; this is the 
only releasable melatonin.  This may be assisted by the presence of canaliculi, non-endothelial lined spaces between 
adjacent pinealocytes, which eventually connect to the third ventricle (B) (Reiter et al., 2014).  Via the CSF, melatonin 
influences the seasonal reproductive responses of photosensitive animals and mediates its effects on circadian biology 
(C).  The non-releasable pool is represented here by the liver and ovary, but also includes every cell in the organism, all 
of which synthesize melatonin intracellularly as well as possibly discharging it into the local cellular microenvironment 
where it has autocrine and paracrine actions without ever entering the general circulation (Reiter et al., 2020a).  
Canaliculi also exist between adjacent hepatocytes (E) by which melatonin may eventually drain into the bile in the 
biliary tree (F); the bile concentration of melatonin is exceptionally high (Tan et al., 1999).  All ovarian cells, including 
the granulosa cells and the oocyte itself synthesize melatonin, from which it may leak (or be released) into the ovarian 
follicular fluid (H); again, however, melatonin produced in the ovarian or any tissue other than the pineal gland does not 
enter the blood.  The non-releasable pool of melatonin has many regulatory actions in the cell in which it is produced as 
illustrated in this review. 
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The light:dark cycle and cancer cell 
mitochondrial dysregulation 
Many solid tumors (Courtnay et al., 2015; 
Abdel-Wahab et al., 2019) and some other 
pathological tissues (Atlante et al., 2017; Burns & 
Manda 2017) abandon mitochondrial glucose 
metabolism and ATP production in favor of 
cytosolic aerobic glycolysis, a phenomenon known 
as the Warburg effect.  This change enhances the 
growth and invasive potential of these cancers and 
aids in tumor growth (Liberti & Locasale 2016; 
Vaupel et al., 2019).  As a result of this switch, 
glucose uptake is markedly accelerated due to 
stimulation of the glucose transporter, GLUT1, in 
the cell membrane (Mayo et al., 2019) and its 
associated conversion to pyruvate.  Additionally, 
the pentose phosphate pathway is highly activated 
which contributes to the production of the 
necessary nucleotides, etc., required for the 
expedited cellular proliferation (Yamamoto et al., 
2018; Jin & Zhou, 2019).  These and other changes 
are depicted in Figure 3. 
Recent studies indicate that melatonin 
from both the releasable and non-releasable pool 
may negate the Warburg effect (Reiter & Rosales-
Corral 2019; Reiter et al., 2019; Puente-Moncada 
et al., 2020).  In the studies in question, numerous 
endpoints indicative of cancer cell metabolism, 
i.e., rapid glucose uptake and lactic acid secretion, 
linoleic acid entrance into the cells and its 
conversion to the mitogenic molecule, 13-
hydroxyoctadecanoic acid (13-HODE), 3H-
thymidine incorporation into DNA, etc., all 
exhibited marked day:night differences (Blask et 
al., 2014).  These reports included investigation of 
three different types of cancer xenotypes that were 
grown subcutaneously in immune-compromised 
rodents (Blask et al., 2014; Mao et al., 2016; 
Dauchy et al., 2018).  During the day, the tumors 
were clearly metabolically highly active and 
underwent Warburg-type metabolism.  Conversely, 
at night, they deserted aerobic glycolysis and 
adopted a conventional normal cell activity.  Thus, 
in the day, these tumors functioned with a cancer 
phenotype while at night they displayed a normal 
metabolic phenotype (Reiter et al., 2019).  To the 
best of our knowledge, no such circadian rhythm 
had been reported for any solid tumor type, 
possibly related to the fact that rarely is 
experimental cancer metabolism investigated at 
night and, moreover, cultured cancer cells would 
not display such fluctuations (Reiter et al., 2020b). 
In these studies, the tumor-bearing 
animals had been kept under a strict light:dark 
cycle and when their blood melatonin levels were 
measured over the 24-hour period, daytime levels 
were uniformly low (associated with intensified 
cancer metabolism) while the dark period was 
accompanied by the usual large surge in blood 
melatonin concentrations (when the cancer cells 
exhibited a more normal-type metabolism) (Blask 
et al., 2014; Mao et al., 2016).  The authors then 
anticipated that the shift in metabolic type may be 
related to the differential day:night melatonin 
concentrations given that melatonin already had a 
long history as an oncostatic agent (Hill et al., 
2015; Li et al., 2017). 
When the nocturnally-elevated blood 
melatonin levels were subdued by contaminating 
the dark period with a low light intensity where the 
melatonin rhythm persisted but at a greatly 
attenuated level, the cancer cell metabolic 
endpoints remained highly elevated throughout the 
24-hour period and tumor growth was advanced 
(Blask et al., 2014).  Thus, extinguishing the large 
day:night difference in circulating melatonin 
clearly related to a more active tumor metabolism 
and provided a likely explanation for the view that 
light pollution exaggerates the frequency or growth 
of human cancers, especially breast cancer 
(Sanchez-Barcelo et al., 2012; Hill et al., 2015). 
While the findings that melatonin 
suppression caused an enhancement of the 
metabolic features, as predicted from the disturbed 
uptake and secretion of several metabolites by the 
tumors (Blask et al., 2014), little evidence was 
provided concerning the changed intracellular 
mechanisms that would account for the 
exaggerated metabolism.  It was obvious, however, 
that the presence or absence of melatonin impacted 
aerobic glycolysis of the tumors (high uptake of 
glucose and elevated lactate secretion). 
 
Melatonin reverses aerobic glycolysis in cancer 
cells 
Based on the findings of Blask et al. 
(2014), Mao and colleagues (2016), and Dauchy 
and coworkers (2018), we proposed that melatonin 
functions like some other drugs (Sutendra & 
Michelakis 2013; Reiter & Rosales-Corral 2019; 
Reiter et al., 2019, 2020b), the so-called 
glycolytics, that are known to influence aerobic 
glycolysis in cancer cells.  As envisioned, 
melatonin either directly or indirectly interferes 
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with the ability of pyruvate dehydrogenase kinase 
(PDK) to suppress pyruvate dehydrogenase 
complex (PDC) which interrupts the conversion of 
pyruvate to acetyl-CoA in the mitochondria.  The 
activation of PDK is well known to downregulate 
PDC, thereby causing cells to adopt cytosolic 
aerobic glycolysis as a means of ATP and 
metabolite production required to meet the energy 
demands of the rapidly proliferating tumor cells 

























Figure 3 This figure illustrates the disrupted metabolism that occurs in the mitochondria of solid tumor cells.  The 
changes involve a shift to glucose oxidation from the mitochondria to the cytosol, a process referred to as aerobic 
glycolysis or the Warburg effect.  When rapidly dividing tumor cells are deprived of an ample oxygen supply (pO2), 
hypoxia inducible factor (HIF-1α) is activated which promotes a number of changes including upregulation of 
inwardly-directed glucose transporter (GLUT) and the outwardly-directed monocarboxylate transporter (MCT4).  This 
allows the rapid influx of glucose and its metabolism to pyruvate.  In normal cells, much of the pyruvate formed enters 
the mitochondria to be converted to acetyl-CoA.  In cancer cells, however, this process is stalemated (red X) because 
the enzyme that metabolizes pyruvate to acetyl-CoA, i.e., pyruvate dehydrogenase complex (PDC), is downregulated.  
As a result, cytosolic pyruvate undergoes conversion to lactic acid with the lactate, which is abundantly released via the 
MCT4, leading to the acidification of the local extracellular microenvironment (Balkwill et al., 2012).  The activated 
HIF-1α also upregulates the gatekeeper enzyme, pyruvate dehydrogenase kinase (PDK), which downregulates pyruvate 
dehydrogenase complex (PDC) accounting for the interruption of the mitochondrial pyruvate to acetyl-CoA conversion.  
Moreover, HIF-1α promotes vascular endothelial growth factor (VEGF) which hastens blood vessel growth into the 
tumor ensuring an improved O2 and nutrient supply and a route for cancer cell metastasis.  To ensure adequate 
molecular building blocks for the rapid cell proliferation, the pentose phosphate pathway enhances nucleotide 
production and the generation of the reducing agent, nicotinamide adenine dinucleotide phosphate hydrogen (NADPH), 
which neutralizes reactive oxygen species (ROS) that could kill cancer cells.  In the mitochondria, the reduced 
production of acetyl-CoA diminishes the citric acid cycle and eventually oxidative phosphorylation (OXPHOS) with a 
lowered mitochondrial energy (ATP) production.  Rather ATP is derived from its production in the cytosol and 
although the yield of ATP is reduced when this occurs, its synthesis is very rapid thus compensating for the loss of 
mitochondrial ATP.  Finally, inadequate mitochondrial acetyl-CoA limits intramitochondrial melatonin production 
since acetyl-CoA is a necessary co-factor for the rate limiting enzyme in melatonin synthesis, arylalkylamine N-
acetyltransferase (AANAT) which metabolizes serotonin (5-HT) to N-acetylserotonin (NAS), the immediate precursor 
of melatonin (Reiter et al., 2019).  The loss of mitochondrial melatonin compromises other metabolic processes in this 
organelle, e.g., optimal function of SIRT3 (not shown).  The boxed items on the right identify some of the consequences 
of the altered metabolism experienced by cancer cells along with the resulting elevation in primary and secondary 
cancer.  In normal cells the blockade of the transfer of pyruvate into the mitochondria is lifted and PDC is not 
downregulated, so the metabolism of pyruvate to acetyl-CoA is ensured.  Thus, all PDC downstream events in the 
mitochondria function differently in normal cells compared to cancer cells. 
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The scheme we proposed would require 
the suppression of PDK which would alleviate the 
inactivation of PDC permitting pyruvate to be 
enzymatically transformed into acetyl-CoA in 
mitochondria thereby reversing the Warburg effect 
(Reiter et al., 2019, 2020b).  PDK is under control 
of several transcription factors which support its 
upregulation (Park et al., 2018).  The most 
noteworthy of these is hypoxia-inducible factor 1α 
(HIF-1α) which not only exaggerates the activity 
of PDK but also stimulates the glucose membrane 
transporters (GLUTs), the activity of lactate 
dehydrogenase (LDH) and the excretion of lactate 
via the monocarboxylate transporter (MCT4) 
(Bensiger & Christofk 2012; Zhang et al., 2013).  
Melatonin, in a number of experimental situations, 
is a proven HIF-1α modulator.  Melatonin 
treatment of ethanol-preferring rats that suffered 
with serous papillary carcinoma reduced HIF-1α 
level in the tumors (Zonta et al., 2017).  Also, HIF-
1α is known to be stabilized in an oxidizing 
environment and melatonin, as a potent scavenger 
of reactive oxygen species (ROS) (Reiter et al., 
2016; Tan & Reiter 2019), would destabilize this 
factor limiting its ability to deactivate PDC (Park 
et al., 2010).  Under other experimental conditions 
as well, melatonin has been repeatedly proven to 
be an inhibitor of HIF-1α (Dai et al., 2008; Cho et 
al., 2011; Lai et al., 2017; Lima Mota 2016).  
Based on the evidence thus far accumulated, HIF-
1α suppression by melatonin is a means by which 
it could regulate PDK/PDC interactions and 
influence glycose metabolism in cancer cells as 
proposed (Reiter et al., 2019, 2020b). 
Other regulators that influence cancer cell 
metabolism which melatonin sways also have been 
identified.  MYC oncogene over expression leads 
to cellular changes compatible with supporting 
aerobic glycolysis; thus, like HIF-1α, it regulates 
PDK, the glucose membrane transporters and, 
additionally, LDH which augments the enzymatic 
conversion of pyruvate to lactate (Dang et al., 
2008) (Figure. 3).  MYC and LDH are known 
melatonin targets under some experimental 
conditions (Sanchez-Sanchez et al., 2015). 
Anderson (2019) and Anderson and 
Reiter (2019) have speculated as to additional 
processes by which melatonin may regulate the 
PDK/PDC axis and mitochondrial metabolism.  In 
this expanded scheme, which would fit with the 
currently-available information, this idea suggests 
the potential involvement of the aryl hydrocarbon 
receptor, the chaperone protein 14-3-3, 
microRNAs and the reversed metabolism of 
melatonin to N-acetylserotonin (NAS) by 
P4501B1.  Accordingly, NAS and/or the 
NAS/melatonin ratio may determine mitochondrial 
metabolism. 
Beyond the ability of melatonin to correct 
cancer cell mitochondrial metabolism via HIF-1α 
inhibition, several reports have shown that the 
regulatory actions of melatonin extend to other 
processes that interfere with cancer cell growth 
(Prieto-Dominguez et al., 2016; Chuffa et al., 
2019; Oliveiro et al., 2016).  Using hepatocellular 
carcinoma cells (114G2), they examined the 
impact of melatonin on HIF-1α and VEGF 
proteins, both of which advance angiogenesis in 
growing tumors.  Under conditions of hypoxia, 
melatonin curtailed the expression of both 
proangiogenic factors.  These findings are 
particularly important in that blood vessel growth 
into growing cancers helps in their nutrient support 
and provides an avenue for metastasis.  Two other 
groups also found that melatonin interferes with 
the activation of HIF-1α under hypoxic conditions 
to curb endothelial growth and blood vessel 
formation (Park et al., 2010; Carbajo-Pescador et 
al., 2013).  Other processes that may bypass HIF-
1α inhibition by melatonin that also block cancer 
growth metastasis have been described (Su et al., 
2017; Goncalvas Ndo et al., 2016; Marques et al., 
2018). 
 
Releasable versus non-releasable melatonin 
pool in regulating cancer cell glucose 
metabolism 
As summarized above, there are two 
pools (circadian and non-circadian) of melatonin 
both of which may influence glucose metabolism 
in cancer cell mitochondria by mechanisms 
involving PDK inhibitions and upregulation of 
PDC.  Mitochondrial melatonin synthesis uses the 
same enzymes as in the pineal gland.  Thus, 
tryptophan is metabolized to serotonin (5-HT) 
which, via a two-step process is converted to 
melatonin utilizing two enzymes, aryl alkyl N-
acetyltransferase (AANAT) and acetylserotonin 
methyltransferase (ASMT) (Ganguly et al., 2002).  
Acetyl-CoA, however, also is a necessary 
co-factor/substrate for the rate limiting enzyme, 
AANAT, in melatonin synthesis.  Since cancer 
cells have a limited transfer of pyruvate into 
mitochondria and its conversion to acetyl-CoA, 
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this organelle is deprived of the required co-factor 
to support the acetylation of 5-HT thereby 
preventing melatonin synthesis (Reiter et al., 2019, 
2020b).  Thus, since cancer cell mitochondria lack 
the melatonin-producing capacity, the circadian 
regulation of Warburg metabolism as reported by 
Blask and coworkers (2014) is likely a 
consequence releasable melatonin derived from the 
pineal gland (Reiter et al., 2019) and taken up by 
the cancer cells (Mocayar-Maron et al., 2019).  In 
contrast, in normal cells where mitochondrial 
acetyl-CoA is abundant, local melatonin synthesis 
occurs unabated as indicated by the uniformly high 
mitochondrial melatonin concentrations throughout 
a light:dark cycle (Venegas et al., 2012; Suofu et 
al., 2017).  A final implication of this is that while 
normal cell mitochondria have an ample supply of 
melatonin, mitochondria of cancer cells may be 
deficient in this important molecule (Reiter et al., 
2019, 2020b) (Figure. 3).  Given melatonin’s 
substantial oncostatic activity, its reduction in 
cancer cells could be a major contribution to cell 
proliferation and metastasis (Huo et al., 2017). 
 
Conclusions 
Melatonin is a documented oncostatic 
agent against a wide variety of experimental cancer 
types, e.g., breast, prostate, pancreatic, colorectal, 
oral, lung, gastric, cervical, etc. (Courtnay et al., 
2015).  The recent demonstration of melatonin 
synthesis in mitochondria may have a direct 
bearing on its ability to modulate both the 
progression and metastasis of cancer.  The means 
by which melatonin reduces cancer involves, as 
with some other agents, its ability to overcome 
aerobic glycolysis (the Warburg effect) as 
considered herein and elsewhere (Reiter et al., 
2019; 2020b).  Reversing the Warburg effect 
redirects pyruvate, the product of glycolysis, to the 
mitochondria for its conversion to acetyl-CoA.  In 
doing so, exogenously administered melatonin not 
only negates cancer cell growth and 
chemoresistance, but also assures acetyl-CoA 
production which feeds into the citric acid cycle 
which, in turn, enhances oxidative phosphorylation 
and ATP synthesis.  Thus, melatonin transforms 
cancer cells into a more normal cell phenotype. 
By improving acetyl-CoA synthesis in 
mitochondria, when blood melatonin (either 
pineal-derived or exogenously administered) enters 
mitochondria, it also supports intramitochondrial 
melatonin production since acetyl-CoA is a 
required co-factor for the rate limiting enzyme in 
melatonin synthesis.  A necessary corollary of this 
is that while healthy cell mitochondria produce 
melatonin, these organelles of cancer cells 
presumably are incapable of doing so at least 
during the day (Reiter et al., 2019).  This loss of 
mitochondrial melatonin in cancer cells may well 
contribute to their ability to rapidly proliferate, 
invade and metastasize.  Similarly, during aging 
when melatonin levels typically drop (presumably 
including melatonin levels in both the releasable 
and non-releasable pool, an elevated propensity for 
cancer initiation, progression and metastasis would 
be anticipated (Almohammed et al., 2020; Lee et 
al., 2020). 
The means by which melatonin enhance 
the conversion of pyruvate to acetyl-CoA likely 
stems from its direct or indirect inhibition of HIF-
1α.  HIF-1α, which is upregulated in cancer cells 
due to hypoxia, normally stimulates the gatekeeper 
enzyme, PDK, which downregulates PDC causing 
the failure of acetyl-CoA production.  These 
mechanisms deserve careful investigation to 
identify how it relates to the oncostatic functions 
of melatonin. 
Finally, increased age is often associated 
with a significant reduction in endogenous 
melatonin production; conversely, many cancer 
types increase in frequency in the elderly.  That 
these two events are functionally linked is not an 
absolute imperative but, based on currently 
available data, it is worthy of consideration.  
Moreover, thought should be given to the idea that 
vitamin D, a molecule produced during the day, 
and melatonin, the chemical expression of 
darkness, functionally interact to maintain healthy 
mitochondria and reduce the risk of cancer (and 
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